Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Ellemunter

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Chronic Illness|June 30, 2014
Patient experience in cystic fibrosis care: Development of a disease-specific questionnaireKatja Stahl, Gratiana Steinkamp, Gerald Ullrich, et al.
Frontiers in Immunology|May 24, 2021
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining FluidJochen G Mainz, Christin Arnold, Kara Wittstock, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 2, 2016
International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcomeAnne Munck, Corinne Alberti, Carla Colombo, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 19, 2016
Low sodium status in cystic fibrosis-as assessed by calculating fractional Na(+) excretion-is associated with decreased growth parametersChristiane Knepper, Helmut Ellemunter, Johannes Eder, et al.
The European Respiratory Journal|April 20, 2013
Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registryEitan Kerem, Laura Viviani, Anna Zolin, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier ParametersMaximilian Zeyda, Andrea Schanzer, Pavel Basek, et al.
Frontiers in Pharmacology|August 19, 2021
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic FibrosisPatrick O Hanafin, Isabelle Sermet-Gaudelus, Matthias Griese, et al.
Pediatric Pulmonology|December 16, 2011
Feasibility and variability of measuring the Lung Clearance Index in a multi-center settingSusanne I Fuchs, Helmut Ellemunter, Johannes Eder, et al.
The Lancet Regional Health. Europe|August 9, 2023
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistrySivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, et al.
Nature Communications|September 16, 2023
Bridging of host-microbiota tryptophan partitioning by the serotonin pathway in fungal pneumoniaGiorgia Renga, Fiorella D'Onofrio, Marilena Pariano, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Chronic Illness|June 30, 2014
Patient experience in cystic fibrosis care: Development of a disease-specific questionnaireKatja Stahl, Gratiana Steinkamp, Gerald Ullrich, et al.
Frontiers in Immunology|May 24, 2021
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining FluidJochen G Mainz, Christin Arnold, Kara Wittstock, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 2, 2016
International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcomeAnne Munck, Corinne Alberti, Carla Colombo, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 19, 2016
Low sodium status in cystic fibrosis-as assessed by calculating fractional Na(+) excretion-is associated with decreased growth parametersChristiane Knepper, Helmut Ellemunter, Johannes Eder, et al.
The European Respiratory Journal|April 20, 2013
Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registryEitan Kerem, Laura Viviani, Anna Zolin, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
Cystic Fibrosis Newborn Screening in Austria Using PAP and the Numeric Product of PAP and IRT Concentrations as Second-Tier ParametersMaximilian Zeyda, Andrea Schanzer, Pavel Basek, et al.
Frontiers in Pharmacology|August 19, 2021
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic FibrosisPatrick O Hanafin, Isabelle Sermet-Gaudelus, Matthias Griese, et al.
Pediatric Pulmonology|December 16, 2011
Feasibility and variability of measuring the Lung Clearance Index in a multi-center settingSusanne I Fuchs, Helmut Ellemunter, Johannes Eder, et al.
The Lancet Regional Health. Europe|August 9, 2023
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistrySivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner, et al.
Nature Communications|September 16, 2023
Bridging of host-microbiota tryptophan partitioning by the serotonin pathway in fungal pneumoniaGiorgia Renga, Fiorella D'Onofrio, Marilena Pariano, et al.
Pageof 5